Alzheimer’s Disease Therapeutics (2022 Edition) – Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)
Executive Summary According to Azoth Analytics research report, the Alzheimer’s disease Therapeutics- Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials. The ... もっと見る
サマリーExecutive SummaryAccording to Azoth Analytics research report, the Alzheimer’s disease Therapeutics- Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials. The Alzheimer’s disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer’s disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease. Alzheimer’s prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades. Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario. Scope of the Report • The report analyses the Alzheimer’s Disease Therapeutics in the Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others). • The report analyses Alzheimer’s disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other). • The report analyses the Alzheimer’s disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical). • The Alzheimer’s Disease Therapeutics- Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA). • The key insights of the report have been presented through the leading company shares. • Also, the major trends, drivers and challenges as well as unmet needs of the industry has been analysed in the report. • The companies analysed in the report include Eli-Lily & Co, Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen. Key Target Audience • Alzheimer’s Disease Therapeutics Companies • End Users (Hospitals and clinics) • Research and Development (R&D) Organizations • Government Bodies & Regulating Authorities • Investment Banks and Equity Firms 目次1. Introduction1.1 Alzheimer's Disease Therapeutics Overview 1.2 Scope of Research 2. Executive Summary 2.1 Market Dashboard 2.2 Regional Insights 2.3 Market Ecosystem Factors 3. Research Methodology 3.1 Data Collection Process 3.2 Market Size Calculation-Top-to-Bottom 4. Macro Economic Indicator Outlook 4.1 Global, Region-wise GDP Growth 4.2 Global Medical Spending 4.3 Current Healthcare Expenditure 4.4 Pharmaceutical Spending/capita 5. Competitive Positioning 5.1 Companies - Product Positioning 5.2 Competitive positioning 5.2.1 Eli-Lily & Co 5.2.2 Elsal Co., Ltd. 5.2.3 BioVie 5.2.4 Johnson & Johnson 5.2.5 Otsuka Pharmaceutical Co., Ltd. 5.2.6 H. Lundbeck A/S 5.2.7 Novartis 5.2.8 Cognition Therapeutics 5.2.9 Merck Sharp & Dohme LLC 5.2.10 Biogen 6. Alzheimer's disease background 6.1 AD Fact Sheet 6.2 Epidemiology 6.3 Causes and Risk Factors 6.4 Diagnosis and Assessment 6.5 Unmet Needs 7. Therapeutics in Pipeline 7.1 Pipeline Scenario 7.2 Alzheimer's Therapeutics Comparative Review 8. Pipeline Analysis 9. Phase I therapeutics Overview 9.1 LY3372993 9.1.1 Drug Description 9.1.2 Outcomes 9.2 Lu AF87908 9.2.2 Drug Description 9.2.3 Outcomes 9.3 anle138b 9.3.1 Drug Description 9.3.2 Outcomes 9.3.3 Collaborators 9.4 ASN51 9.4.1 Drug Description 9.4.2 Outcomes 9.4.3 Collaborators 9.5 CMS121 9.5.1 Drug Description 9.5.2 Outcomes 9.5.3 Collaborators 9.6 IBC-Ab002 9.6.1 Drug Description 9.6.2 Outcomes 9.6.3 Collaborators 9.7 LX1001 9.7.1 Drug Description 9.7.2 Outcomes 9.8 MK-2214 9.8.1 Drug Description 9.8.2 Outcomes 9.9 MK-8189 9.9.1 Drug Description 9.9.2 Outcomes 9.10 ACU193 9.10.1 Drug Description 9.10.2 Outcomes 9.10.3 Collaborators 9.11 NIO752 9.11.1 Drug Description 9.11.2 Outcomes 9.12 ALN-APP 9.12.1 Drug Description 9.12.2 Outcomes 9.13 TB006 9.13.1 Drug Description 9.13.2 Outcomes 9.14 SNK01 9.14.1 Drug Description 9.14.2 Outcomes 9.15 Pepinemab 9.15.1 Drug Description 9.15.2 Outcomes 9.15.3 Collaborators 9.16 GB-5001 9.16.1 Drug Description 9.16.2 Outcomes 9.17 AC-1202 9.17.1 Drug Description 9.17.2 Outcomes 9.18 SHR-1707 9.18.1 Drug Description 9.18.2 Outcomes 9.19 BEY2153 9.19.1 Drug Description 9.19.2 Outcomes 9.20 JNJ-40346527 9.20.1 Drug Description 9.20.2 Outcomes 9.20.3 Collaborators 9.21 APNmAb005 9.21.1 Drug Description 9.21.22 Outcomes 9.22 NPT 2042 9.22.1 Drug Description 9.22.2 Outcomes 9.23 ALZ-101 9.23.1 Drug Description 9.23.2 Outcomes 10. Phase I/II therapeutics Overview 10.1 Posiphen 10.1.1 Drug Description 10.1.2 Outcomes 10.1.3 Collaborators 10.2 PrimeProô/ PrimeMSKô 10.2.1 Drug Description 10.2.2 Outcomes 10.2.3 Collaborators 10.3 TB006 10.3.1 Drug Description 10.3.2 Outcomes 10.4 RO7126209 10.4.1 Drug Description 10.4.2 Outcomes 10.5 DNL593 10.5.1 Drug Description 10.5.2 Outcomes 10.5.3 Collaborators 10.6 BIIB080 10.6.1 Drug Description 10.6.1 Outcomes 10.7 E2814 10.7.1 Drug Description 10.7.2 Outcomes 10.8 Tdap 10.8.1 Drug Description 10.8.2 Outcomes 10.8.3 Collaborators 10.9 ACI-35.030/ JACI-35.054 10.9.1 Drug Description 10.9.2 Outcomes 10.9.3 Collaborators 10.10 ACI-24.060 10.10.1 Drug Description 10.10.2 Outcomes 10.10.3 Collaborators 10.11 IVL3003 10.10.1 Drug Description 10.10.2 Outcomes 11. Phase II therapeutics Overview 11.1 Lecanemab 11.1.1 Drug Description 11.1.2 Outcomes 11.1.3 Collaborators 11.2 Lomecel-B 11.2.1 Drug Description 11.2.2 Outcomes 11.2.3 Collaborators 11.3 AL002 11.3.1 Drug Description 11.3.2 Outcomes 11.3.3 Collaborators 11.4 AL001 11.4.1 Drug Description 11.4.2 Outcomes 11.5 CT1812 (Elaya) 11.5.1 Drug Description 11.5.2 Outcomes 11.6 APH-1105 11.6.1 Drug Description 11.6.2 Outcomes 11.7 ATH-1017 11.7.1 Drug Description 11.7.2 Outcomes 11.8 T-817MA 11.8.1 Drug Description 11.8.2 Outcomes 11.9 Montelukast buccal film 11.9.1 Drug Description 11.9.2 Outcomes 11.10 ABBV-916 11.10.1 Drug Description 11.10.2 Outcomes 11.11 Bepranemab 11.11.1 Drug Description 11.11.2 Outcomes 11.12 TB006 11.12.1 Drug Description 11.12.2 Outcomes 11.13 LY3372689 11.13.1 Drug Description 11.13.2 Outcomes 11.14 MW150 11.14.1 Drug Description 11.14.2 Outcomes 11.14.3 Collaborators 11.15 EX039 11.15.1 Drug Description 11.15.2 Outcomes 11.15.3 Collaborators 11.16 JNJ-42847922 11.16.1 Drug Description 11.16.2 Outcomes 11.17 REM0046127 11.17.1 Drug Description 11.17.2 Outcomes 11.18 Bryostatin 1 11.18.1 Drug Description 11.18.2 Outcomes 11.18.3 Collaborators 11.19 NanoLithiumÆ NP03 11.19.1 Drug Description 11.19.2 Outcomes 11.20 AstroStem 11.20.1 Drug Description 11.20.2 Outcomes 11.21 Gantenerumab 11.21.1 Drug Description 11.21.2 Outcomes 11.22 Semorinemab 11.22.1 Drug Description 11.22.1 Outcomes 11.23 Obicetrapib 11.23.1 Drug Description 11.23.2 Outcomes 11.24 ALZ-801 11.24.1 Drug Description 11.24.2 Outcomes 11.25 CY6463 11.25.1 Drug Description 11.25.2 Outcomes 11.26 Crenezumab 11.26.1 Drug Description 11.26.2 Outcomes 11.26.3 Collaborators 11.27 T3D-959 11.27.1 Drug Description 11.27.2 Outcomes 11.28 PMZ-1620 11.28.1 Drug Description 11.28.2 Outcomes 11.29 GV1001 11.29.1 Drug Description 11.29.2 Outcomes 11.30 ACZ885 11.30.1 Drug Description 11.30.2 Outcomes 11.31 PQ912 11.31.1 Drug Description 11.31.2 Outcomes 11.31.3 Collaborators 11.32 APH-1105 11.32.1 Drug Description 11.32.2 Outcomes 11.33 SLS-005 11.33.1 Drug Description 11.33.2 Outcomes 11.33.3 Collaborators 11.34 Flos gossypii flavonoids 11.34.1 Drug Description 11.34.2 Outcomes 11.34.3 Collaborators 11.35 Human Mesenchymal Stem cells (MSCs), 11.35.1 Drug Description 11.35.2 Outcomes 11.36 JNJ-63733657 11.36.1 Drug Description 11.36.2 Outcomes 11.37 IGC-AD1 11.37.1 Drug Description 11.37.2 Outcomes 11.38 TW001 11.38.1 Drug Description 11.38.2 Outcomes 11.39 ABvac40 11.39.1 Drug Description 11.39.2 Outcomes 12. Phase II/III therapeutics Overview 12.1 Tricaprilin 12.1.1 Drug Description 12.1.2 Outcomes 12.2 ANAVEX2-73 12.2.1 Drug Description 12.2.3 Outcomes 12.3 Piromelatine 12.3.1 Drug Description 12.3.2 Outcomes 12.3.3 Collaborators 12.4 AGB101 12.4.1 Drug Description 12.4.2 Outcomes 12.4.3 Collaborators 13. Phase III therapeutics Overview 13.1 Simufilam 13.1.1 Drug Description 13.1.2 Outcomes 13.1.3 Collaborators 13.2 ATH-1017 13.2.1 Drug Description 13.2.2 Outcomes 13.3 Lecanemab 13.3.1 Drug Description 13.3.2 Outcomes 13.3.3 Collaborators 13.4 Nilotinib BE 13.4.1 Drug Description 13.4.2 Outcomes 13.4.3 Collaborators 13.5 Brexpiprazole 13.5.1 Drug Description 13.5.2 Outcomes 13.5.3 Collaborators 13.6 Masitinib 13.6.1 Drug Description 13.6.2 Outcomes 13.7 Remternetug 13.7.1 Drug Description 13.7.2 Outcomes 13.8 Donanemab 13.8.1 Drug Description 13.8.2 Outcomes 13.9 NE3107 13.9.1 Drug Description 13.9.2 Outcomes 13.10 Gantenerumab 13.10.1 Drug Description 13.10.2 Outcomes 13.11 GV-971 13.11.1 Drug Description 13.11.2 Outcomes 13.12 Aducanumab 13.12.1 Drug Description 13.12.2 Outcomes 13.13 TRx0237 13.13.1 Drug Description 13.13.2 Outcomes 13.14 Semagludtide 13.14.1 Drug Description 13.14.2 Outcomes 13.15 BPDO-1603 13.15.1 Drug Description 13.15.2 Outcomes 13.16 AR1001 13.16.1 Drug Description 13.16.2 Outcomes 13.17 KarXT 13.17.1 Drug Description 13.17.2 Outcomes 13.18 AXS-05 13.18.1 Drug Description 13.18.2 Outcomes 14. Phase IV therapeutics Overview 14.1 Choline Alfoscerate 14.1.1 Drug Description 14.1.2 Outcomes 14.2 Ebicomb 14.2.1 Drug Description 14.2.2 Outcomes 14.3 Rivastigmine 14.3.1 Drug Description 14.3.2 Outcomes 14.4 GV-971 14.4.1 Drug Description 14.4.2 Outcomes 15. Preclinical Phase therapeutics Overview 15.1 PMN310 15.1.1 Drug Description 15.1.2 Outcomes 15.1.3 Collaborators 15.2 PRX123 15.2.1 Drug Description 15.2.2 Outcomes 16. Pipeline analysis, By molecule type 16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type 17. Pipeline Analysis, By Route of Administration 17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Azoth Analytics社の医療・製薬分野での最新刊レポート
本レポートと同じKEY WORD(alzheimers disease)の最新刊レポート
よくあるご質問Azoth Analytics社はどのような調査会社ですか?調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |